0001104659-18-025639.txt : 20180420
0001104659-18-025639.hdr.sgml : 20180420
20180420165307
ACCESSION NUMBER: 0001104659-18-025639
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180418
FILED AS OF DATE: 20180420
DATE AS OF CHANGE: 20180420
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vaughn Victor
CENTRAL INDEX KEY: 0001567077
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35518
FILM NUMBER: 18767317
MAIL ADDRESS:
STREET 1: C/O SUPERNUS PHARMACEUTICALS, INC.
STREET 2: 1550 EAST GUDE DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001356576
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 1550 E GUDE DR
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 301-838-2500
MAIL ADDRESS:
STREET 1: 1550 E GUDE DR
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
4
1
a4.xml
4
X0306
4
2018-04-18
0
0001356576
SUPERNUS PHARMACEUTICALS INC
SUPN
0001567077
Vaughn Victor
C/O SUPERNUS PHARMACEUTICALS, INC.
1550 EAST GUDE DRIVE
ROCKVILLE
MD
20850
0
1
0
0
Sr. VP of Sales & Marketing
Common Stock
2018-04-18
4
M
0
6250
12.98
A
15594
D
Common Stock
2018-04-18
4
M
0
3750
25.30
A
19344
D
Common Stock
2018-04-18
4
S
0
10000
47.0617
D
9344
D
Common Stock
2018-04-19
4
M
0
7850
25.30
A
17194
D
Common Stock
2018-04-19
4
S
0
7850
49.0261
D
9344
D
Employee Stock Option (Right to Buy)
12.98
2018-04-18
4
M
0
6250
0
D
2026-03-01
Common Stock
6250
25000
D
Employee Stock Option (Right to Buy)
25.30
2018-04-18
4
M
0
3750
0
D
2027-02-24
Common Stock
3750
46250
D
Employee Stock Option (Right to Buy)
25.30
2018-04-19
4
M
0
7850
0
D
2027-02-24
Common Stock
7850
38400
D
Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.25, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.15, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted.
The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted.
/s/ Gregory S. Patrick, as attorney-in-fact
2018-04-20